trial summary · NCT07646821
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
Trial record from the TrialBase DB dataset, status RECRUITING, condition Ropeginterferon, sponsored by M.D. Anderson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to control the disease.
Source record: https://clinicaltrials.gov/study/NCT07646821
Facts
| registry id | NCT07646821 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Ropeginterferon |
| sponsor | M.D. Anderson Cancer Center |
| sponsor class | OTHER |
| enrollment | 30 |
| start date | 2026-10-27 |
| primary completion | 2028-12-11 |
| completion | 2030-12-11 |
| results posted | not reported |
Conditions
- Ropeginterferon
- Alfa-2b
- Azacitidine
- MDS/AML
Interventions
- ropeginterferon alfa- 2b
- Azacitidine (AZA)
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.